The Min Lu Research Group

Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
State Key Laboratory of Omics and Disease (formerly State Key Laboratory of Medical Genomics)

The Min Lu Research Group

Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
State Key Laboratory of Omics and Disease (formerly State Key Laboratory of Medical Genomics)

Shujun Xiao

Postdoctoral Researcher

Research Direction

Small molecule targeted drugs

Lead the project

2023 Shanghai Science and Technology Commission Qimingxing (24YF2725300), host

2023 China Postdoctoral Science Foundation General Support (2024M762021), led by

2022 Ruijin Hospital Youth Fund Cultivation Program (2024PY059), led by

Representative Honor Award

2024 Shanghai “Super Postdoctoral Fellow”

2024 Shanghai Science and Technology Innovation Action Plan: Rising Stars

2024 Outstanding Doctoral Dissertation at Shanghai Jiao Tong University

2024 Shanghai Outstanding Graduates

2023 Shanghai Institute of Hematology Outstanding Talent Award Fund (Chen Zhu and Chen Saijuan Award Fund) First Prize

2022 Shanghai Jiao Tong University President’s Award

Apply For A Patent

1. Lu Min, Liang Ying, Xiao Shujun; Multi functional p53 resurrection drugs and their uses, June 11, 2021, ZL202110659536.4

2. Lu Min, Xiao Shujun, Shi Fangfang, Wang Zhengyuan; A method for designing and screening compounds that bind to target proteins using HomoArt, December 22, 2024, 2024, 24119069869

3. Lu Min, Dong Jiajia, Wu Jiaqi, Li Qianqian, Chen Xueqin, Jiang Ying, Zheng Derun, Guo Taijie, Xiao Shujun, Ma Tiancheng; Multivalent molecular gel compounds and their preparation and application, September 27, 2024, pp. 2411363354.2
Publish A Paper
  1. Xiao S#, Shi F#, Song H#, …, Lu M*. Characterization of the generic mutant p53-rescue compounds in a broad range of assays. Cancer Cell. 2024 Mar 11;42(3):325-327（第一作者，IF=48.8）
  2. Song H#, Xiao S#, Wu J#, Lu M*. Drugging p53: Barriers, Criteria, and Prospects. Cancer Discov. 2024 Nov 1;14(11):2055-2060（共同第一，IF=30.6）
  3. Wu J#, Song H#, Xiao S#, Lu M*. Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies. Nat Rev Cancer. 2025 May 16. （共同第一，IF=72.5）
  4. Li J#, Xiao S#, Shi F#, …, Lu M*. Arsenic trioxide extends survival of Li-Fraumeni syndrome mimicking mouse. Cell Death Dis. 2023 Nov 29;14(11):783（共同第一，IF=9.0）
  5. Tang Y#, Song H#, Wang Z#, …, Lu M*. Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations. Cell Rep. 2022 Apr 12;39(2):110622（共同第一，IF=10.0）
  6. Tang Y#, Xiao S#, Wang Z, …, Lu M*. A Prognostic Model for Acute Myeloid Leukemia Based on IL-2/STAT5 Pathway-Related Genes. Front Oncol. 2022 Feb 2;12:785899.（共同第一，IF=5.7）
  7. Song H#, Wu J#, Tang Y#, …, Lu M*. Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties. Sci Transl Med. 2023 Apr 5;15(690):eabn9155（共同作者，IF=17.1）
  8. Chen S#, Wu JL#, Liang Y#, …, Lu M*. Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site. Cancer Cell. 2021 Feb 8;39(2):225-239.e8（共同作者，IF=48.8）
  9. Liang Y#, An Q#, Song H#*, …, Lu M*. AcGlcAs: A Novel P53-Targeting Arsenical with Potent Cellular Uptake and Cancer Cell Selectivity. J Med Chem. 2023 Dec 28;66(24):16579-16596（共同作者，IF=7.3）
  10. Yan N#, Li Y#, Xing Y, …, Lu M*. Developmental arsenic exposure impairs cognition, directly targets DNMT3A, and reduces DNA methylation. EMBO Rep. 2022 Jun 7;23(6):e54147（共同作者，IF=9.4）

The Min Lu Research Group

Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
State Key Laboratory of Omics and Disease (formerly State Key Laboratory of Medical Genomics)
  • 021-64370045 
  • min.lu@@shsmu.edu.cn
  • No. 197, Ruijin Er Road, Huangpu District, Shanghai, China

The Min Lu Research Group©️Copyright